NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America
2003

NmcA Carbapenem-Hydrolyzing Enzyme in Enterobacter cloacae

Sample size: 1 publication Evidence: moderate

Author Information

Author(s): Pottumarthy Sudha, Moland Ellen Smith, Juretschko Stefan, Swanzy Susan R., Thomson Kenneth S., Fritsche Thomas R.

Primary Institution: University of Washington School of Medicine

Hypothesis

The study investigates the presence and characteristics of the NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae isolates in North America.

Conclusion

The NmcA enzyme was identified in a clinical isolate of Enterobacter cloacae in North America, indicating a need for further investigation into its distribution and clinical impact.

Supporting Evidence

  • The NmcA enzyme was confirmed through various analytical methods including isoelectric focusing and molecular sequencing.
  • The isolate was resistant to imipenem but susceptible to other antibiotics.
  • This is the first report of the NmcA enzyme in North America, highlighting its clinical significance.
  • The enzyme was found to be inducible by cefoxitin and imipenem.

Takeaway

Doctors found a new enzyme in a germ that makes it hard to treat infections, which is important for understanding how to fight these germs.

Methodology

The study involved isolating the E. cloacae strain from a patient, performing susceptibility testing, and using molecular techniques to confirm the presence of the NmcA enzyme.

Limitations

The study does not establish whether the NmcA enzyme was solely responsible for the carbapenem resistance in the isolate.

Participant Demographics

A 33-year-old man with acute myeloid leukemia.

Digital Object Identifier (DOI)

10.3201/eid0908.030096

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication